Our previous work has shown that GLP-1 RAs make up 5% of prescriptions within the US (although this trend has increased, as seen in the latest GLP-1 prescribing and dispense report)
Demand is exploding Science is evolving And current therapies are not perfect Kaileras playbook is clear: Dual GLP-1 + GIP mechanism (ribupatide) Longer-lasting effect Better tolerability Oral + injectable formats This is not disruption
Available from: Fletcher AL, Lowen TE, Sakkal S, Reiseger JJ, Hammett MV, Seach N, et al
Genetic factors, including mutations in SNCA, LRRK2, and VPS35, promote -synuclein aggregation into Lewy bodies and neurites
Speak to a provider today to find the most effective weight loss plan
12.01.23 Lawyers request lawsuit consolidation Plaintiff lawyers requested the consolidation of pending GLP-1 RA lawsuits into an MDL